WO2018004237A1 - Composition comprenant un exosome dérivé de cellules souches traitées par la thrombine pour le traitement d'une plaie de la peau - Google Patents
Composition comprenant un exosome dérivé de cellules souches traitées par la thrombine pour le traitement d'une plaie de la peau Download PDFInfo
- Publication number
- WO2018004237A1 WO2018004237A1 PCT/KR2017/006776 KR2017006776W WO2018004237A1 WO 2018004237 A1 WO2018004237 A1 WO 2018004237A1 KR 2017006776 W KR2017006776 W KR 2017006776W WO 2018004237 A1 WO2018004237 A1 WO 2018004237A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thrombin
- stem cells
- derived
- exosome
- exosomes
- Prior art date
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 116
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 79
- 108090000190 Thrombin Proteins 0.000 title claims abstract description 69
- 229960004072 thrombin Drugs 0.000 title claims abstract description 69
- 206010072170 Skin wound Diseases 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims description 17
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 21
- 230000033115 angiogenesis Effects 0.000 claims abstract description 16
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000003102 growth factor Substances 0.000 claims description 16
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 14
- 210000003491 skin Anatomy 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 11
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 11
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 11
- 210000004700 fetal blood Anatomy 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 10
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 10
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 10
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 10
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 10
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 10
- 229940053128 nerve growth factor Drugs 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 238000005119 centrifugation Methods 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 238000004113 cell culture Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- -1 patches Substances 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 4
- 210000004556 brain Anatomy 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000003076 neurotropic agent Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 210000002536 stromal cell Anatomy 0.000 claims description 4
- 210000001691 amnion Anatomy 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 210000002894 multi-fate stem cell Anatomy 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 210000005036 nerve Anatomy 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000003954 umbilical cord Anatomy 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 210000004027 cell Anatomy 0.000 abstract description 33
- 230000000694 effects Effects 0.000 abstract description 16
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 208000005623 Carcinogenesis Diseases 0.000 abstract description 2
- 206010052779 Transplant rejections Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000036952 cancer formation Effects 0.000 abstract description 2
- 231100000504 carcinogenesis Toxicity 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 210000002950 fibroblast Anatomy 0.000 description 12
- 230000029663 wound healing Effects 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 102000004889 Interleukin-6 Human genes 0.000 description 7
- 108090001005 Interleukin-6 Proteins 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010021143 Hypoxia Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007954 hypoxia Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000002792 vascular Effects 0.000 description 5
- 230000002491 angiogenic effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102100025222 CD63 antigen Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004504 adult stem cell Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002487 multivesicular body Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007388 punch biopsy Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000007560 devascularization Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011542 limb amputation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000013630 prepared media Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
Definitions
- the present invention in the pharmaceutical composition for the prevention or treatment of skin wounds (Skin Wound), including a exosome derived from thrombin-treated stem cells as an active ingredient, pharmaceutical preparations containing the same, and a method for preparing the same It is about.
- the skin is the body's primary defense against disease as a protective barrier to the body, and the epidermis provides a barrier to microbial invasion.
- the primary objectives in the treatment of wounds, burns, abrasions and other damage to the skin are rapid closure and wound healing to prevent infection.
- Wound healing is generally a complex process that involves three stages: inflammation, proliferation, and remodeling.
- the first step involves clotting to achieve haemostasis, and supplementation of neutrophils to destroy bacteria and necrotic tissue, followed by supplementation of macrophages.
- angiogenesis occurs, in which endothelial cells migrate to the wound site, and at the same time fibroblasts move to the wound site to help produce granulation tissue.
- the formation of granulation tissue allows for re-epithelialization.
- the level of collagen production and destruction is evened, and the wound healed is slowly changed to achieve maximum strength. Wound healing can be chronic or even delayed or damaged when one of the processes fails to function properly in a timely manner.
- Chronic wounds are defined as open wounds that require more than 8 weeks of treatment, and the damaged healing process can often be associated with diabetes complications, with severe consequences such as high limb amputation and even death. This can be done. Approximately 15% of diabetics suffer from chronic wounds that do not heal. Therefore, wounds are an important issue not only for individuals but also for society, and early treatment should reduce the risk of secondary infection.
- ECM extra-cellular matrix
- stem cells are known to be involved in tissue regeneration, treatment, and immune response, as well as their multipotency, and by using such characteristics to separate and culture mesenchymal stem cells from umbilical cord blood, bone marrow, etc. Efforts have been made to develop a treatment for the disease.
- cell therapeutics cannot rule out the possibility of tumorogenicity due to DNA transfer, and secondly, stem cells themselves can cause vascular obstruction or myocardial infarction. Third, cord blood and Rejection reaction due to surface antigen when transplanted (allograft) using the same allogeneic cells is a problem. Fourth, in general, cell therapeutics are difficult to manufacture and have high storage costs due to the limitation of storage transport. There is a limit.
- Exosomes are small vesicles (approximately 30-100 nm in diameter) that are secreted from a variety of cells, and within the cells called multivesicular bodies (MVBs), rather than falling directly off the plasma membrane in an electron microscope study. Originated from specific compartments and released and secreted out of cells was observed. In other words, when fusion occurs between the polycystic body and the plasma membrane, the vesicles are released into the extracellular environment, which is called an exosome. It is not clear what molecular mechanism these exosomes are made of, but not only red blood cells, but also various immune cells and tumor cells, including B-lymphocytes, T-lymphocytes, dendritic cells, platelets, macrophages, etc. Stem cells are also known to produce and secrete exosomes in living conditions.
- exosomes derived from stem cells contain nuclear components as well as receptors and proteins are known to play an intercellular communication role.
- the exosomes derived from the stem cells contain a relatively small amount of animal serum compared to the stem cells may also exclude the risk of symptoms (zoonosis) due to animal serum infection.
- cell therapy using exosomes is expected to become a new paradigm that can overcome the limitations of existing stem cell therapy.
- Korean Patent Publication No. 2012-0133709 discloses a skin regeneration effect of exosomes obtained from skin cells, but it is completely known that exosomes derived from thrombin-treated stem cells are superior to conventional skin wound treatment. There is no bar.
- the present inventors have conducted extensive studies to improve the treatment efficacy while overcoming the limitations of the stem cell therapeutics with respect to skin wounds, and thus, exosomes derived from stem cells, especially exosomes derived from stem cells treated with thrombin.
- the present invention was completed by confirming that this angiogenesis and skin wound healing effect was significantly increased.
- the present invention provides a pharmaceutical composition for preventing or treating skin wounds, including an exosome derived from thrombin-treated stem cells as an active ingredient.
- the stem cells are stem selected from the group consisting of mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells and multipotent stem cells It is characterized by being a cell.
- the mesenchymal stem cells are characterized in that derived from the umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerves, skin, amniotic membrane or placenta.
- the treatment of the cutaneous wound is characterized by angiogenesis due to vascular endothelial cell growth promotion.
- the skin wound is characterized by a defect in the epidermis, dermis or subcutaneous tissue.
- the pharmaceutical composition is characterized by being administered orally or parenterally.
- the pharmaceutical composition is characterized in that it further comprises an auxiliary component selected from the group consisting of culture medium, cytokines, growth factors and genes.
- the exosomes are characterized by increased expression of growth factors, immunoregulatory factors, antioxidant factors or angiogenesis factors.
- the growth factor is a brain-derived neurotropic factor (BDNF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), nerve growth factor (NGF), or vascular endothelial growth (VEGF). factor).
- BDNF brain-derived neurotropic factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- NGF nerve growth factor
- VEGF vascular endothelial growth
- the present invention also provides a pharmaceutical formulation for preventing or treating a skin wound, containing the composition.
- the preparation is characterized in that the injection, injection, spray, liquid or patch form.
- the preparation is characterized in that it further comprises a pharmaceutically acceptable carrier.
- the present invention also provides a quasi-drug preparation for improving skin wounds, comprising an exosome derived from thrombin-treated stem cells as an active ingredient.
- the improvement of the skin wound is characterized in that by angiogenesis (angiogenesis).
- the exosomes are characterized by increased expression of growth factors, immunoregulatory factors, antioxidant factors or angiogenesis factors.
- the quasi-drug preparation is in the form of an external preparation for skin selected from the group consisting of liquids, ointments, creams, sprays, patches, gels and aerosols.
- the present invention (a) treating the thrombin after stem cell culture; (b) separating the exosomes from the culture medium of step (a); And (c) preparing a composition containing the exosomes separated in step (b) as an active ingredient.
- the thrombin of step (a) is characterized in that contained in the medium at a concentration of 1-1000 unit / ml.
- the exosome of step (c) is characterized in that using centrifugation.
- the centrifugation is characterized in that it is performed for 10 minutes to 5 hours at 5,000-500,000g.
- the present invention also provides a method for treating a skin wound, comprising administering to a subject an exosome derived from a thrombin-treated stem cell.
- the present invention also provides the use of exosomes derived from thrombin treated stem cells for use in the preparation of an agent for preventing or treating a skin wound.
- the cell-free preparation does not contain DNA, there is no risk of carcinogenesis and there is no cell surface antigen, so there is no problem of rejection reaction.
- the size is very small than the cell there is no fear of causing blockage in the microvascular system during systemic administration, it is possible to reduce the manufacturing cost because it is possible to develop the drug to off the shelf product as a non-cell separation material.
- the exosome derived from the stem cells treated with thrombin is superior to the untreated stem cells, the effect of treating skin wounds is excellent even with a small amount, thereby significantly reducing the amount of stem cells required to generate a therapeutic dose of exosomes. There is an advantage that can significantly lower the cost of therapeutic production.
- the present invention can significantly improve the therapeutic efficacy while solving the problems of the conventional stem cell therapeutics, it can be usefully used for the treatment of skin wounds.
- FIG. 2 is a Western blot result confirming that exosome markers CD63 and CD9 are normally expressed in thrombin-treated stem cell-derived exosomes.
- BDNF growth factors
- FGF growth factor
- HGF growth factor
- NGF growth factor
- VEGF anti-inflammatory cytokines
- IL-6 anti-inflammatory cytokines
- FIG. 4A is a result of a tube formation assay showing that exosomes derived from thrombin-treated stem cells exert a concentration-dependent angiogenic effect
- FIG. 4B is a graph quantifying them.
- FIG. 5A is a result of a tube formation assay showing a difference in angiogenic effects depending on the type of cell from which the exosome is derived
- FIG. 5B is a graph quantifying it.
- Figure 6a is a result showing the skin wound healing effect on exosomes derived from thrombin-treated stem cells in an in vivo skin wound animal model
- Figure 6b is a graph quantifying it.
- FIG. 7 shows fibroblast exosomes derived from fibroblasts, naive MSC exosomes derived from untreated thrombin stem cells, thrombin MSC exosomes derived from thrombin treated stem cells and hypoxia in an in vivo skin wound animal model. This is a result of comparing the healing effect of skin wounds of stem cell-derived exosomes (hypoxia MSC exosome).
- the present invention provides a pharmaceutical composition for preventing or treating skin wounds, including an exosome derived from thrombin-treated stem cells as an active ingredient.
- 'stem cell' refers to a cell having an ability to differentiate into two or more different types of cells while having an autologous ability as an undifferentiated cell.
- Stem cells of the present invention may be autologous or allogeneic stem cells, may be from any type of animal, including humans and non-human mammals, and is not limited to whether the stem cells are derived from adults or embryos Do not.
- Stem cells of the present invention include embryonic stem cells or adult stem cells, preferably adult stem cells.
- the adult stem cells may be mesenchymal stem cells, human tissue-derived mesenchymal stromal cells, human tissue-derived mesenchymal stem cells or multipotent stem cells, preferably mesenchymal stem cells, but is not limited thereto. It doesn't work.
- the mesenchymal stem cells may be mesenchymal stem cells derived from umbilical cord, umbilical cord blood, bone marrow, fat, muscle, nerve, skin, amnion, and placenta, but is not limited thereto.
- 'umbilical cord blood means blood collected from the umbilical vein connecting the placenta and the fetus.
- Umbilical cord blood is a naturally occurring by-product of childbirth and is much easier to collect than normal mesenchymal tissue such as bone marrow, which requires multiple surgeries. It is also easy to get.
- cord blood-derived cells do not express histocompatibility antigen HLA-DR (class II), which is the most important cause of rejection in tissue or organ transplantation, immunity such as rejection that has been a problem during conventional transplantation The reaction can be induced or minimized, so that not only autologous umbilical cord blood but also taga-derived cord blood can be used.
- 'exosome' refers to a small (approximately 30-100 nm diameter) vesicle of membrane structure secreted from various cells, and the vesicle is released into the extracellular environment due to the fusion of the polycystic body and the plasma membrane. Means.
- the exosomes are naturally secreted or include those secreted artificially.
- skin wound is meant to include defects of the epidermis, dermis or subcutaneous tissue.
- prevention or treatment of skin wounds is meant to include the reduction, alleviation and improvement of symptoms of skin wounds, and to include a lowering the possibility of skin wounds.
- vascular endothelial cells HUVEC
- Angiogenesis is a phenomenon in which endothelial cells of existing blood vessels decompose, move, divide, and differentiate extracellular matrix to form new capillaries, which are essential in the physiological process of wound healing. By doing so, the effect of wound healing can be verified. That is, angiogenesis must be involved in the necessary wound healing process for the rejuvenation of wounded skin tissue.
- inflammatory reactions occur due to necrosis of cells and destruction of blood vessels. After this inflammatory response, kallikrein, thrombin, and plasmin, together with devascularization of blood components, activation of platelets and coagulation, The same biological media goes through a series of processes.
- stem cell function / efficacy is increased due to an increase in paracrine property, which is the main mechanism of action of stem cells, without altering cell stability such as cell viability and oxidative function. Can be enhanced. Furthermore, due to thrombin treatment, as well as enhancing the therapeutic efficacy of exosomes derived from stem cells, it is possible to increase the secretion amount of exosomes.
- the paracrine may be increased growth factor, immunoregulatory factor, antioxidant factor or regenerative factor
- growth factor refers to a proteinaceous bioactive substance that promotes cell division, growth, or differentiation, and is referred to as BDNF (brain-derived).
- BDNF brain-derived
- neurotropic factor fibroblast growth factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- NGF nerve growth factor
- VEGF vascular endothelial growth factor
- IL-6 Interleukin-6
- vascular endothelial growth factor is a representative protein that regulates angiogenesis.
- VEGF binds to VEGF receptors 1, 2, or 3 (VEGFR1, VEGFR2, VEGFR3) present in vascular endothelial cells to induce tyrosine phosphorylation of VEGF receptors (VEGFR) resulting in activation of vascular endothelial cells. This will have a significant impact on.
- compositions of the present invention can be administered to a subject in various ways without particular limitation, for example, orally or parenterally.
- the pharmaceutical composition of the present invention may further contain one or more known auxiliary ingredients having a therapeutic effect on the skin wound together with the stem cell-derived exosomes.
- genes that are effective in treating skin wounds eg, anti-inflammatory cytokine genes, siRNAs for inflammatory cytokines or anti-sense primers
- Expression vectors eg, cytokines (eg, interleukin-10), growth factors (eg, keratinocyte growth factor) that provide autocrine or paracrine effects, and these At least one auxiliary ingredient selected from the group consisting of a combination may be further included.
- Preferred dosages of the pharmaceutical compositions of the present invention depend on the condition and weight of the individual, the extent of the disease, the form of the drug, the route of administration and the duration and can be appropriately selected by those skilled in the art. Administration of the composition may be administered once a day, may be divided several times, but is not limited thereto.
- the pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the treatment of skin wounds.
- composition of the present invention may further comprise a suitable carrier commonly used in the manufacture of pharmaceutical compositions.
- a suitable carrier commonly used in the manufacture of pharmaceutical compositions.
- a preservative, a painless agent, a solubilizer, or a stabilizer may be further included, and in the case of a topical administration, a base, an excipient, a lubricant, or a preservative may be further included.
- compositions of the present invention can be administered in a dosage form, formulated in a unit dosage form suitable for administration in the body of a subject according to conventional methods in the pharmaceutical art.
- Formulations suitable for this purpose include parenteral injectables such as injectable ampoules, injectables such as infusion bags, sprays such as aerosol preparations and the like.
- the injection ampoule may be mixed with the injection solution immediately before use, and physiological saline, glucose, Ringer's solution, etc. may be used as the injection solution.
- the infusion bag may be made of polyvinyl chloride or polyethylene.
- Administration in the present invention means providing the subject with the compositions of the present invention in any suitable manner.
- Preferred dosages of the pharmaceutical compositions of the present invention depend on the condition and weight of the individual, the extent of the disease, the form of the drug, the route of administration and the duration and can be appropriately selected by those skilled in the art. Administration of the composition may be administered once a day, may be administered several times, but is not limited thereto.
- the present invention also provides a quasi-drug preparation for improving skin wounds, comprising an exosome derived from thrombin-treated stem cells as an active ingredient.
- the quasi-drug preparation may be in the form of an external preparation for skin selected from the group consisting of liquids, ointments, creams, sprays, patches, gels, and aerosols, and specifically, antiseptic cleaners, shower foams, gagrins, wipes, detergent soaps, and hands. It can be used as a wash, humidifier filler, mask, ointment or filter filler composition.
- the present invention (a) treating the thrombin after stem cell culture; (b) separating the exosomes from the culture medium of step (a); And (c) preparing a composition containing the exosomes separated in step (b) as an active ingredient.
- the thrombin treatment concentration is sufficient to enhance the efficacy of stem cells / exosomes, and there is no particular limitation, but is preferably included in the concentration of 1-1000 unit / ml in the medium.
- centrifugation for example, in a culture medium, centrifugation, ultrafast centrifugation, filtration by filter, gel filtration chromatography, pre-flow electrophoresis, capillary electrophoresis, using a polymer Separation may be carried out using a method such as separation and a combination thereof, preferably centrifugation / supercentrifugation.
- centrifugation / supercentrifugation is preferably performed at 4 ° C. and 3,000-100,000 g for 10 minutes to 5 hours.
- the medium used for cell culture in the present invention is a cell such as stem cells in vitro containing elements essential for growth and proliferation of cells such as sugars, amino acids, various nutrients, serum, growth factors, minerals, and the like. Means a mixture for growth and propagation.
- DMEM Dulbecco's Modified Eagle's Medium
- MEM Minimal Essential Medium
- BME Base Medium Eagle
- RPMI1640 DMEM / F-10 (Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-10)
- DMEM / F-12 Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12
- ⁇ -MEM ⁇ -Minimal Essential Medium
- G-MEM Gasgow's Minimal Essential Medium
- IMOC Isocove's Modified Dulbecco's Medium
- KnockOut DMEM Commercially prepared media such as, but not limited to, artificially synthesized media, and the like.
- the present invention also provides a method for treating a skin wound, comprising administering to a subject an exosome derived from a thrombin-treated stem cell.
- ⁇ means a subject in need of treatment for a disease, and more specifically, human or non-human primates, mice, rats, dogs, cats, horses and cattle, etc. Mean mammal.
- Human umbilical cord blood-derived mesenchymal stem cells (3 ⁇ 10 5 cells) were cultured in 100 mm culture dishes (orange scientific cat # 4450200) for 1 week after dispensing. After confirming that the cells were saturated and propagated in the culture dish, the cells were replaced with MEM alpha media in which 50 unit / ml thrombin (REYON Pharmaceutical. Co., LTD) was diluted and incubated for 6 hours. .
- the culture solution was divided into centrifuge tubes, centrifuged at 4 ° C. and 6,000 rpm for 30 minutes, and the supernatant was transferred to a new tube to remove cell debris. Again, the supernatant was ultracentrifuged at 4 ° C., 100,000 rpm for 2-4 hours, and then the supernatant was further removed to obtain an exosome (final concentration: 15 ⁇ g / ml).
- the expression of known exosome markers CD63 and CD9 was verified through Western blot.
- the exosomes obtained from the thrombin-treated stem cells normally expressed CD63 and CD9, confirming that the exosomes.
- Example 1-1 Exosome obtained in Example 1-1 was confirmed whether the expression of growth factors or anti-inflammatory cytokines such as IL-6 was increased by the thrombin treatment.
- the proteins in the exosomes are separated and the amount of BDNF, FGF, HGF, NGF, VEGF, IL-6 in the exosomes is determined using the Procarta immunoassay kit ( affymatrix, USA).
- BDNF brain-derived neurotropic factor
- FGF fibroblast growth factor
- HGF hepatocyte growth factor
- NGF hepatocyte growth factor
- VEGF vascular endothelial growth factor
- IL-6 Interleukin-6 expression was increased compared to exosomes (control, normal) obtained from the thrombin untreated stem cells.
- thrombin treatment enhances cell regeneration, vascular regeneration, and anti-inflammatory efficacy of stem cell-derived exosomes.
- human umbilical vein endothelial cells were cultured in Medium 200PRF medium containing Low Serum Growth Supplement (LSGS) for 12 hours, then collected by trypsin treatment, and containing 5% fetal calf serum. Resuspended in M199 medium. Growth factor reduction Matrigel was aliquoted into 250 ⁇ l each in 24 cell culture wells and polymerized in a 37 ° C. CO 2 incubator.
- LSGS Low Serum Growth Supplement
- HUVEC cells were placed in wells with polymerized matrigel at a concentration of 4 ⁇ 10 4 cells per well, and 2.5 ug / ml, 5 ug / ml, 10 of the 'exosomes derived from thrombin-treated stem cells' obtained in Example 1 were obtained. ug / ml concentration was added. After incubation in a 37 ° C. CO 2 incubator for 24 hours, the culture was photographed ( ⁇ 40) and the length of the formed tube was measured using the Image J (National Institute of Health) open program.
- 'exosomes derived from thrombin-treated stem cells' of the present invention induces differentiation of dose-dependent vascular endothelial cells as compared to the control group (untreated group NC) Increased tube formation.
- exosomes derived from untreated thrombin (MSC ECV)
- exosomes derived from thrombin treated stem cells (MSC throm ECV)
- fibroblast ECV exosomes derived from untreated thrombin
- exosomes derived from thrombin treated fibroblast Experiments were carried out in the same manner as in Example 2-1, except that (fibroblast throm ECV) was each treated at a concentration of 10 ug / ml.
- exosomes obtained from the thrombin-treated stem cells of the present invention, significantly improved angiogenesis compared to exosomes (MSC ECV) obtained from thrombin untreated stem cells Showed ability.
- the exosomes obtained from fibroblast did not exhibit any angiogenic capacity regardless of the presence or absence of thrombin treatment, and thus the specific therapeutic efficacy according to the type / capacity of the cells from which the exosomes are derived (angiogenic capacity). It can be seen that this is determined.
- a skin model was prepared by punching the skin with a 0.8 mm biopsy punch on the back of an adult rat, and then fibroblast-derived exosomes (fibroblast exosomes), thrombin-untreated stem cells-derived exosomes (naive MSC exosomes), Thrombin-treated stem cell-derived exosomes (thrombin MSC exosomes) were each mixed with 20 ug of saline, prepared in a total of 10 ul, and then applied to the wound surface.
- fibroblast exosomes fibroblast exosomes
- thrombin-untreated stem cells-derived exosomes thrombin-untreated stem cells-derived exosomes
- thrombin MSC exosomes Thrombin-treated stem cell-derived exosomes
- the exosome (thrombin MSC exosome) obtained from the thrombin-treated stem cells of the present invention the wound significantly improved compared to the exosome (naive MSC exosome) obtained from the thrombin untreated stem cells It showed a therapeutic effect.
- the exosomes obtained from the fibroblast was found to exhibit no wound healing effect similar to the control (saline).
- the wound control group which was damaged by punch biopsy of the skin as compared to the normal group, showed no recovery to normal skin tissue.
- the wound control group which was damaged by punch biopsy of the skin as compared to the normal group, showed no recovery to normal skin tissue.
- the thrombin-treated stem cell-derived exosomes (naive MSC exosome) and hypoxia pretreated stem cell-derived exosomes (hypoxia MSC exosome) showed a tendency to improve somewhat
- thrombin-treated stem cell-derived exosomes thrombin MSC exosome
- the therapeutic efficacy is specifically determined according to the type / capacity of the cell from which the exosome is derived.
- the stem cell-derived exosome-based therapeutic agent treated with the thrombin according to the present invention, it is possible to remarkably improve the treatment efficacy while solving problems such as transplant rejection reaction or manufacturing cost, which is a problem of conventional stem cell therapeutics, It can be usefully used for treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une composition pharmaceutique comprenant un exosome dérivé d'une cellule souche traitée par la thrombine en tant qu'ingrédient efficace pour prévenir ou traiter une plaie cutanée, une formulation pharmaceutique le contenant, et un procédé de production de celle-ci. En tant qu'agent acellulaire, un agent thérapeutique à base d'exosome de la présente invention présente un faible risque de carcinogenèse et aucun problème de rejet de greffe ainsi que peu susceptible de se produire dans l'obstruction microvasculaire. L'agent, qui n'est pas une cellule, mais un matériau isolé à partir d'une cellule, peut être soumis à un développement de médicament en un produit hors d'étagère qui permet de réduire le coût de production. L'agent présente l'avantage de présenter des effets remarquables de traitement de l'angiogenèse et de plaie cutanée même à une faible concentration d'exosomes grâce à l'effet de traitement de la thrombine.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17820513.4A EP3479831B1 (fr) | 2016-07-01 | 2017-06-27 | Composition comprenant un exosome dérivé de cellules souches traitées par la thrombine pour l'utilisation dans le traitement d'une plaie de la peau |
| JP2018568285A JP6826135B2 (ja) | 2016-07-01 | 2017-06-27 | トロンビン処理幹細胞に由来するエクソソームを含む皮膚傷治療用組成物 |
| US16/314,725 US12239695B2 (en) | 2016-07-01 | 2017-06-27 | Composition comprising thrombin-treated stem cell-derived exosome for treating skin wound |
| CN201780047575.0A CN109641013B (zh) | 2016-07-01 | 2017-06-27 | 包含凝血酶处理干细胞来源的外泌体的皮肤创伤的治疗用组合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0083703 | 2016-07-01 | ||
| KR20160083703 | 2016-07-01 | ||
| KR10-2017-0080366 | 2017-06-26 | ||
| KR1020170080366A KR101860266B1 (ko) | 2016-07-01 | 2017-06-26 | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018004237A1 true WO2018004237A1 (fr) | 2018-01-04 |
Family
ID=60787334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2017/006776 WO2018004237A1 (fr) | 2016-07-01 | 2017-06-27 | Composition comprenant un exosome dérivé de cellules souches traitées par la thrombine pour le traitement d'une plaie de la peau |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018004237A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020070700A3 (fr) * | 2018-10-04 | 2020-05-14 | Exogenus Therapeutics, Sa | Compositions comprenant de petites vésicules extracellulaires dérivées de cellules mononucléaires du sang de cordon ombilical ayant des propriétés anti-inflammatoires et immunomodulatrices, et leur procédé d'obtention |
| EP4137140A4 (fr) * | 2020-04-14 | 2024-05-22 | Samsung Life Public Welfare Foundation | Composition de prévention ou de traitement d'une maladie de la peau diabétique, comprenant un exosome dérivé de cellule souche traitée par de la thrombine |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120133709A (ko) | 2011-05-31 | 2012-12-11 | 손대락 | 플럭스 게이트 센서 및 그를 이용한 센싱방법 |
| US20150125950A1 (en) * | 2012-05-18 | 2015-05-07 | Agency For Science, Technology And Research (A*Sta (A*Star) | Umbilical cord mesenchymal stem cell exosomes |
| WO2015088288A1 (fr) * | 2013-12-12 | 2015-06-18 | 사회복지법인 삼성생명공익재단 | Procédé pour favoriser la génération d'exosome dérivé de cellule souche à l'aide de thrombine |
-
2017
- 2017-06-27 WO PCT/KR2017/006776 patent/WO2018004237A1/fr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120133709A (ko) | 2011-05-31 | 2012-12-11 | 손대락 | 플럭스 게이트 센서 및 그를 이용한 센싱방법 |
| US20150125950A1 (en) * | 2012-05-18 | 2015-05-07 | Agency For Science, Technology And Research (A*Sta (A*Star) | Umbilical cord mesenchymal stem cell exosomes |
| WO2015088288A1 (fr) * | 2013-12-12 | 2015-06-18 | 사회복지법인 삼성생명공익재단 | Procédé pour favoriser la génération d'exosome dérivé de cellule souche à l'aide de thrombine |
Non-Patent Citations (4)
| Title |
|---|
| LUO, G. ET AL.: "Promotion of Cutaneous Wound Healing by Local Application of Mesenchymal Stem Dells Derived from Human Umbilical Cord Blood", WOUND REPAIR AND REGENERATION, vol. 18, 2010, pages 506 - 513, XP055092435 * |
| See also references of EP3479831A4 * |
| ZHANG, B. ET AL.: "HucMSC-exosome Mediated-Wnt4 Signaling is Required for Cutaneous Wound Healing", STEM CELLS, vol. 33, 2015, pages 2158 - 2168, XP055522539 * |
| ZHANG, B. ET AL.: "Human Umbilical Cord Mesenchymal Stem Cell Exosomes Enhance Angiogenesis Through the Wnt4/beta-catenin Pathway", STEM CELLS TRANSLATIONAL MEDICINE, vol. 4, 2015, pages 513 - 522, XP055522194 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020070700A3 (fr) * | 2018-10-04 | 2020-05-14 | Exogenus Therapeutics, Sa | Compositions comprenant de petites vésicules extracellulaires dérivées de cellules mononucléaires du sang de cordon ombilical ayant des propriétés anti-inflammatoires et immunomodulatrices, et leur procédé d'obtention |
| EP4137140A4 (fr) * | 2020-04-14 | 2024-05-22 | Samsung Life Public Welfare Foundation | Composition de prévention ou de traitement d'une maladie de la peau diabétique, comprenant un exosome dérivé de cellule souche traitée par de la thrombine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101860266B1 (ko) | 트롬빈 처리 줄기세포에서 유래된 엑소좀을 포함하는 피부상처 치료용 조성물 | |
| WO2017179840A1 (fr) | Composition pour le traitement d'une maladie pulmonaire chronique, comprenant un exosome dérivé de cellules souches traitées par la thrombine | |
| WO2018131779A1 (fr) | Composition pour traiter l'ehi du nouveau-né | |
| WO2015088288A1 (fr) | Procédé pour favoriser la génération d'exosome dérivé de cellule souche à l'aide de thrombine | |
| WO2021210872A1 (fr) | Composition de prévention ou de traitement d'une maladie de la peau diabétique, comprenant un exosome dérivé de cellule souche traitée par de la thrombine | |
| Perrucci et al. | Cyclophilin A modulates bone marrow-derived CD117+ cells and enhances ischemia-induced angiogenesis via the SDF-1/CXCR4 axis | |
| WO2018004237A1 (fr) | Composition comprenant un exosome dérivé de cellules souches traitées par la thrombine pour le traitement d'une plaie de la peau | |
| WO2019004792A9 (fr) | Procédé de préparation et utilisation d'un microsphéroïde de cellule souche cardiaque d'origine humaine | |
| WO2014185620A1 (fr) | Composition de cellules souches pour administration veineuse | |
| WO2020222483A1 (fr) | Composition pharmaceutique pour le traitement de la septicémie ou du syndrome de réponse inflammatoire systémique, comprenant des mitochondries isolées en tant que principe actif | |
| US20200155607A1 (en) | Enriched Cellular Compositions and Therapeutic Use | |
| WO2014057097A1 (fr) | Cellules souches mésenchymateuses modulées pour la thérapie cellulaire cardiaque | |
| WO2013125899A1 (fr) | Composition pour prévention ou traitement de maladies immunitaires ou inflammatoires, contenant des cellules souches comme principe actif | |
| El Mohtadi | Effect of estrogen on host-pathogen interactions in ex vivo and in vitro models of the inflammatory phase of age-related impaired healing | |
| WO2016049485A1 (fr) | Traitement de l'ulcère du pied diabétique au moyen de cellules souches placentaires | |
| WO2022055238A1 (fr) | Composition destinée au traitement de maladies osseuses comprenant un exosome dérivé d'une cellule souche mésenchymateuse adipeuse épidurale | |
| WO2022114730A2 (fr) | Composition pour le traitement de maladies infectieuses, comprenant des exosomes dérivés de cellules souches traitées par la thrombine | |
| WO2024186031A1 (fr) | Composition comprenant un milieu conditionné par des mastocytes pour la cicatrisation des plaies | |
| WO2010123243A2 (fr) | Composition contenant un extrait de testicule pour le traitement ou la prévention de maladies | |
| WO2023182609A1 (fr) | Composition pour favoriser l'angiogenèse, comprenant des cellules souches mésenchymateuses dérivées de tissu adipeux et une fraction vasculaire stromale humaine | |
| Lunardon | In vitro investigation of the therapeutic potential of canine platelet lysate in wound healing | |
| WO2024225832A1 (fr) | Procédé de production en masse de vésicules extracellulaires dérivées de cellules souches, et cellules souches pour la production de vésicules extracellulaires |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17820513 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2018568285 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2017820513 Country of ref document: EP Effective date: 20190201 |